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A 51-year-old female patient was evaluated for a painful chest wall
mass causing atelectasis of the right lung, pleural effusion, and
dyspnea. The patient’s history was significant for esthesioneuroblas-
toma at the age of 24; multiple recurrences of the tumor had been
treated with surgery, radiotherapy, and chemotherapy. Surgical re-
section of the chest wall mass relieved her symptoms and improved
her quality of life. Histologic examination confirmed metastatic
esthesioneuroblastoma. The patient developed generalized disease
and finally died 2 years after surgery. This case demonstrates the
long natural history of this rare neoplasm and the need for close
follow-up of patients so that they can be treated early.
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Esthesioneuroblastoma (ENB), also known as olfactoryneuroblastoma, is a rare tumor arising from the olfactory
epithelium. This tumor is considered locally invasive and the
development of distant metastases after successful treatment
of primary disease carries a grave prognosis. Multimodality
treatment is most often employed for the management of
metastatic disease.1 We present a case of ENB metastatic to
the chest wall.
CASE REPORT
A 51-year-old woman presented to the thoracic surgery
department with dyspnea and a painful chest wall mass,
approximately 20 cm in its largest diameter.
The patient had been diagnosed with a Kadish stage C
ENB at the age of 24. Initial treatment with surgery and
radiotherapy had been successful, but the patient experienced
local recurrence 8 years later (Figure 1). A number of drugs
were given including cisplatin, bleomycin, cyclophospha-
mide, vincristine, 5-fluorouracil, epirubicin, vinblastine, and
procarbazine. Response was observed with cyclophospha-
mide, and her disease remained under control for 4 years,
until local tumor progression was documented again, at
which time she was treated with high-dose melphalan with
autologous bone marrow rescue. Imaging with computed
tomography showed stable disease, and the patient underwent
salvage maxillectomy and radiotherapy. Local control was
achieved, but the patient developed distant metastases at the
thoracic and lumbar vertebrae 11 years later. Radiotherapy
was administered, and the patient remained apparently dis-
ease free for another 4 years, when she developed a chest wall
mass causing persistent pain.
Computed tomography (Figure 2) of the chest revealed
a huge chest wall tumor, pleural effusion, and compression
atelectasis of the right lung. Pleural fluid cytology was non-
diagnostic, whereas fine needle aspiration of the mass re-
vealed neoplastic cells, suggesting the presence of metastatic
disease. Clinical examination and imaging studies did not
reveal other sites of disease. Due to the relatively long
disease-free intervals that had previously been achieved be-
tween recurrences and the large size of the tumor, it was
decided that excision of the mass would be beneficial, pro-
viding at least symptomatic palliation. A thoracoabdominal
incision was made, and the pleural fluid was evacuated. The
tumor extended from the fifth intercostal space to the costal
cartilage, invading the right hemidiaphragm but not the liver
(Figure 3). A wide excision of the chest wall, from the fourth
rib to the costal cartilage, was performed. Tumor-free mar-
gins were confirmed by frozen section. The chest wall and the
diaphragm were reconstructed with the use of polytetrafluo-
roethylene synthetic grafts. The patient was extubated 24
hours after surgery and had an uneventful recovery.
RESULTS
Histologic examination and immunohistochemical
staining revealed the tumor to be a 22-cm metastatic lesion
with features compatible with ENB invading the chest wall.
The patient remained disease free and asymptomatic for
8 months, when a single submandibular lymph node metas-
tasis developed, which was treated with local radiotherapy.
Soon afterward, the patient developed extensive tumor spread
that responded to three cycles of chemotherapy with cisplatin
and etoposide. The duration of response, however, was short,
and finally the patient died 2 years after surgery, 29 years
after the initial diagnosis.
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DISCUSSION
ENB is a rare tumor of the nasal cavity arising from the
olfactory epithelium. The current standard of treatment for
primary disease consists of surgery using a combined cranio-
facial approach followed by radiotherapy.1 The craniofacial
approach was introduced in 1976 by researchers at the Uni-
versity of Virginia. Our patient was treated with extracranial
surgery only, which is associated with a significantly shorter
5-year survival rate compared to the combined approach
(37.5% versus 82%).2
Most reports consider ENB to be locally invasive.
Distant metastases after locoregional control has been
achieved are reported in approximately 8% of patients and
confer a grave prognosis. Among the sites most often in-
volved are the lungs and the vertebrae.3 In a recent series of
30 ENB patients treated at a single institution, only one
patient developed distant metastasis to the spine 12.91 years
after her initial diagnosis with a Kadish stage C tumor. The
patient had a complicated history with multiple recurrences.
The investigators commented that “ENB may not be as prone
to metastasize distally as previously reported.”4 Similarly,
our patient was diagnosed with a locally advanced primary
tumor and had a complicated course with several regional and
distant recurrences for 29 years.
Because of the rarity of ENB and the relatively small
number of patients presenting with metastatic disease, man-
agement remains controversial. We chose a radical surgical
approach because it was considered the only way to effec-
tively offer palliation and possibly prolong survival, taking
into consideration the large size of the tumor. The role of
chemotherapy has not been properly defined in the literature.
A study of chemotherapy in patients with locally advanced
disease demonstrated that platinum-based regimens may in-
duce remission but cannot be considered curative.5 Our pa-
tient, when treated with cisplatin and etoposide for dissemi-
nated disease, demonstrated significant improvement, but the
duration of response was short. It should be noted that the
patient had been extensively treated with a variety of drugs
after the first local recurrence.
Results from a meta-analysis1 suggest that diagnosis of
ENB warrants long-term follow-up due to the long natural
history of the disease. We believe that the present case,
representing one of the most protracted ENB histories in the
literature, confirms this observation.
In conclusion, we present the case of a patient who,
over the course of 29 years since initial diagnosis with ENB,
was managed with all major modalities of cancer therapy for
local, regional, and distant recurrences. This multidisci-
plinary cancer approach was able to achieve disease control
for a protracted period with an acceptable quality of life.
Surgical resection of a late chest wall metastasis provided
symptomatic palliation but was not curative. The natural
history of the disease necessitates long-term surveillance
beginning as early as possible to manage recurrent disease.
FIGURE 1. Magnetic resonance imaging demonstrating a
large tumor originating from the nasal cavity and invading
the base of the skull and the upper maxilla. The low quality
of the image is a reminder that in 1985 magnetic resonance
imaging was still in its infancy.
FIGURE 2. Chest computed tomography confirming the
presence of a huge chest wall tumor and a massive pleural
effusion causing right lower lobe atelectasis.
FIGURE 3. Chest wall tumor resected along with the right
hemidiaphragm. The arrow indicates the abdominal surface
of the diaphragm.
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